Sex-Gender Differences in Irritable Bowel Syndrome

Young Sun Kim, Nayoung Kim, Young Sun Kim, Nayoung Kim

Abstract

Because of the sex-gender differences that are shown in a diversity of physiological and psychological factors, it can be speculated that the clinical presentation of symptoms as well as treatment strategies in women and men with irritable bowel syndrome (IBS) may differ. Studies have revealed that IBS is more common in women than men. As for the IBS subtype, IBS with constipation is significantly more prevalent among women than men. Sex hormones and gender differences may play important roles in the pathophysiology of IBS. However, its pathophysiologic mechanisms still remain largely unknown, and therapeutic implications are limited. Moreover, women IBS patients have been reported to feel more fatigue, depression, anxiety, and lower quality of life than men IBS patients. Furthermore, there has been evidence of differences in the appropriate treatment efficacy to IBS in men and women, although relatively few men are enrolled in most relevant clinical trials. A more sex-gender-oriented approach in the medical care setting could improve understanding of heterogeneous patients suffering from IBS. An individualized and multicomponent approach including sex and gender issues might help improve the treatment of IBS.

Keywords: Gender; Hormones; Irritable bowel syndrome; Sex.

Conflict of interest statement

Conflicts of interest: None.

Figures

Figure 1
Figure 1
Flow chart documenting the results of the search strategy.
Figure 2
Figure 2
Brain-gut axis and sex hormones interaction in irritable bowel syndrome (IBS). Sex hormones influence peripheral and central regulatory mechanisms involved in the pathophysiology of IBS contributing to the alterations in stress response, visceral sensitivity and motility, intestinal barrier function, and immune activation of intestinal mucosa. Sex hormones also have direct effects on the gut microbiota and enteric nervous system. E, estradiol; T, testosterone; P, progesterone; CRH, corticotropin-releasing hormone; ACTH, adrenocorticotropic hormone; GTP, guanosine-5’-triphosphate; CCK, cholecystokinin; PG, prostaglandin; 5-HT, 5-hydroxytryptamine; ER, estrogen receptor; DRG, dorsal root ganglion; JAM, junctional adhesion molecule. Adapted from Meleine and Matricon.

References

    1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional Bowel Disorders. Gastroenterology. 2006;130:1480–1491. doi: 10.1053/j.gastro.2005.11.061.
    1. Houghton LA, Heitkemper M, Crowell M, et al. Age, gender and women’s health and the patient. Gastroenterology. 2016;150:1332–1343. e4. doi: 10.1053/j.gastro.2016.02.017.
    1. Wizemann TM, Pardue ML. Exploring the biological contributions to human health: does sex matter? Washington, DC: National Academies Press; 2001.
    1. Kim YS, Kim N, Kim GH. Sex and gender differences in gastroesophageal reflux disease. J Neurogastroenterol Motil. 2016;22:575–588. doi: 10.5056/jnm16138.
    1. Kilminster S, Downes J, Gough B, Murdoch-Eaton D, Roberts T. Women in medicine is there a problem? A literature review of the changing gender composition, structures and occupational cultures in medicine. Medical Educ. 2007;41:39–49. doi: 10.1111/j.1365-2929.2006.02645.x.
    1. Annandale E, Hammarström A. Constructing the ‘gender-specific body’: a critical discourse analysis of publications in the field of gender-specific medicine. Health. 2011;15:571–587. doi: 10.1177/1363459310364157.
    1. Ahlawat SK, Cuddihy MT, Locke GR., 3rd Gender-related differences in dyspepsia: a qualitative systematic review. Gender Med. 2006;3:31–42. doi: 10.1016/S1550-8579(06)80192-0.
    1. Flier SN, Rose S. Is functional dyspepsia of particular concern in women? A review of gender differences in epidemiology, pathophysiologic mechanisms, clinical presentation, and management. Am J Gastroenterol. 2006;101(12 suppl):S644–S653. doi: 10.1111/j.1572-0241.2006.01015.x.
    1. Welén K, Faresjö A, Faresjö T. Functional dyspepsia affects women more than men in daily life: a case-control study in primary care. Gender Med. 2008;5:62–73. doi: 10.1016/S1550-8579(08)80009-5.
    1. Boeckxstaens GE, Drug V, Dumitrascu D, et al. Phenotyping of subjects for large scale studies on patients with IBS. Neurogastroenterol Motil. 2016;28:1134–1147. doi: 10.1111/nmo.12886.
    1. Talley NJ. Irritable bowel syndrome: definition, diagnosis and epidemiology. Baillieres Best Pract Res Clin Gastroenterol. 1999;13:371–384. doi: 10.1053/bega.1999.0033.
    1. Chial HJ, Camilleri M. Gender differences in irritable bowel syndrome. J Gend Specif Med. 2002;5:37–45.
    1. Lovell RM, Ford AC. Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol. 2012;107:991–1000. doi: 10.1038/ajg.2012.131.
    1. Song KH, Jung HK, Kim HJ, et al. Clinical practice guidelines for irritable bowel syndrome in Korea, 2017 revised edition. J Neurogastroenterol Motil. 2018;24:197–215. doi: 10.5056/jnm17145.
    1. Chang L, Heitkemper MM. Gender differences in irritable bowel syndrome. Gastroenterology. 2002;123:1686–1701. doi: 10.1053/gast.2002.36603.
    1. Adeyemo MA, Spiegel BM, Chang L. Meta-analysis: do irritable bowel syndrome symtomes vary between men and wome? Aliment Pharmacol Ther. 2010;32:738–755. doi: 10.1111/j.1365-2036.2010.04409.x.
    1. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002;123:2108–2131. doi: 10.1053/gast.2002.37095.
    1. Müller-Lissner SA, Bollani S, Brummer RJ, et al. Epidemiological aspects of irritable bowel syndrome in Europe and North America. Digestion. 2001;64:200–204. doi: 10.1159/000048862.
    1. Sperber AD, Dumitrascu D, Fukudo S, et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a rome foundation working team literature reviw. Gut. 2017;66:1075–1085. doi: 10.1136/gutjnl-2015-311240.
    1. Ghoshal UC, Abraham P, Bhatt C, et al. Epidemiological and clinical profile of irritable bowel syndrome in India: report of the India society of gastroenterology task force. Indian J Gastroenterol. 2008;27:22–28.
    1. Lee OY. Asian motility studies in irritable bowel syndrome. J Neurogastroenterol Motil. 2010;16:120–130. doi: 10.5056/jnm.2010.16.2.120.
    1. Toner BB, Akman D. Gender role and irritable bowel syndrome: literature review and hypothesis. Am J Gastroenterol. 2000;95:11–16. doi: 10.1111/j.1572-0241.2000.01698.x.
    1. Jung HK. Epidemiology of gastroesophageal reflux disease in Asia: a systematic review. J Neurogastroenterol Motil. 2011;17:14–27. doi: 10.5056/jnm.2011.17.1.14.
    1. Klem F, Wadhwa A, Prokop LJ, et al. Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis. Gastroenterology. 2017;152:1042–1054.e1. doi: 10.1053/j.gastro.2016.12.039.
    1. Mulak A, Taché Y. Sex difference in irritable bowel syndrome: do gonadal hormones play a role? Gastroenterol Pol. 2010;17:89–97.
    1. García Rodríguez LA, Ruigómez A, Wallander MA, Johansson S, Olbe L. Defection of colorectal tumor and inflammatory bowel disease during follow-up of patients with initial diagnosis of irritable bowel syndrome. Scand J Gastroenterol. 2000;35:306–311. doi: 10.1080/003655200750024191.
    1. Heitkemper MM, Chang L. Do fluctuations in ovarian hormones affect gastrointestinal symptoms in women with irritable bowel syndrome? Gend Med. 2009;6(suppl 2):152–167. doi: 10.1016/j.genm.2009.03.004.
    1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480–1491. doi: 10.1053/j.gastro.2005.11.061.
    1. Mulak A, Waszczuk E, Paradowski L. Irritable bowel syndrome as an interdisciplinary clinical problem. Adv Clin Exp Med. 2008;17:667–675.
    1. Warnock JK, Clayton AH. Chronic episodic disorders in women. Psychiatr Clin North Am. 2003;26:725–740. doi: 10.1016/S0193-953X(03)00042-X.
    1. Chang L, Toner BB, Fukudo S, et al. Gender, age, society, culture, and the patient’s perspective in the functional gastrointestinal disorders. Gastroenterology. 2006;130:1435–1446. doi: 10.1053/j.gastro.2005.09.071.
    1. Georgescu D, Reisz D, Gurban CV, et al. Migraine in young females with irritable bowel syndrome: still a challenge. Neuropsychiatr Dis Treat. 2017;14:21–28. doi: 10.2147/NDT.S144955.
    1. Olafsdottir LB, Gudjonsson H, Jonsdottir HH, Björnsson E, Thjodleifsson B. Natural history of irritable bowel syndrome in women and dysmenorrhea: a 10-year follow-up study. Gastroenterol Res Pract. 2012;2012 doi: 10.1155/2012/534204. 534204.
    1. Choghakhori R, Abbasnezhad A, Amani R, Alipour M. Sex-related differences in clinical symptoms, quality of life, and biochemical factors in irritable bowel syndrome. Dig Dis Sci. 2017;62:1550–1560. doi: 10.1007/s10620-017-4554-6.
    1. Heitkemper MM, Cain KC, Jarrett ME, Burr RL, Hertig V, Bond EF. Symptoms across the menstrual cycle in women with irritable bowel syndrome. Am J Gastroenterol. 2003;98:420–430. doi: 10.1111/j.1572-0241.2003.07233.x.
    1. Ruigómez A, García Rodríguez LA, Johansson S, Wallander MA. Is hormone replacement therapy associated with an increased risk of irritable bowel syndrome? Maturitas. 2003;44:133–140. doi: 10.1016/S0378-5122(02)00321-3.
    1. Gonenne J, Esfandyari T, Camilleri M, et al. Effect of female sex hormone supplementation and withdrawal on gastrointestinal and colonic transit in postmenopausal women. Neurogastroenterol Motil. 2006;18:911–918. doi: 10.1111/j.1365-2982.2006.00808.x.
    1. Chandar AK. Diagnosis and treatment of irritable bowel syndrome with predominant constipation in the primary-care setting: focus on linaclotide. Int J Gen Med. 2017;10:385–393. doi: 10.2147/IJGM.S126581.
    1. Harris LA, Umar SB, Baffy N, Heitkemper MM. Irritable bowel syndrome and female patients. Gastroenterol Clin North Am. 2016;45:179–204. doi: 10.1016/j.gtc.2016.02.001.
    1. Drossman DA. Functional Gastrointestinal disorder: history, pathophysiology, and Rome IV. Gastroenterology. 2016;150:1262–1279. doi: 10.1053/j.gastro.2016.02.032.
    1. Farhadi A, Banton D, Keefer L. Connecting our gut feeling and how our gut feels: the role of well-being attributes in irritable bowel syndrome. J Neurogastroenterol Motil. 2018;24:289–298. doi: 10.5056/jnm17117.
    1. Meerveld BG, Johnson AC. Mechanisms of stress-induced visceral pain. J Neurogastroenterol Motil. 2018;24:7–18. doi: 10.5056/jnm17137.
    1. Lee HF, Liu PY, Wang YP, Tsai CF, Chang FY, Lu CL. Sexual abuse is associated withan abnormal psychological profile and sleep difficulty in patients with irritable bowel syndrome in Taiwan. J Neurogastroenterol Motil. 2018;24:79–86. doi: 10.5056/jnm17004.
    1. Choi YJ, Kim N, Yoon H, et al. Overlap between irritable bowel syndrome and functional dyspepsia including subtype analyses. J Gastroenterol Hepatol. 2017;32:1553–1561. doi: 10.1111/jgh.13756.
    1. Lampe JW, Fredstrom SB, Slavin JL, Potter JD. Sex differences in colonic function: a randomised trial. Gut. 1993;34:531–536. doi: 10.1136/gut.34.4.531.
    1. Meleine M, Matricon J. Gender-related differences in irritable bowel syndrome: potential mechanisms of sex hormones. World J Gastroenterol. 2014;20:6725–6743. doi: 10.3748/wjg.v20.i22.6725.
    1. Aloisi AM. Gonadal hormones and sex differences in pain reactivity. Clin J Pain. 2003;19:168–174. doi: 10.1097/00002508-200305000-00004.
    1. Cairns BE, Gazerani P. Sex-related differences in pain. Maturitas. 2009;63:292–296. doi: 10.1016/j.maturitas.2009.06.004.
    1. Houghton LA, Jackson NA, Whorwell PJ, Morris J. Do male sex hormones protect from irritable bowel syndrome? Am J Gastroenterol. 2000;95:2296–2300. doi: 10.1111/j.1572-0241.2000.02314.x.
    1. Kim BJ, Rhee PL, Park JH, et al. Male sex hormones may influence the symptoms of irritable bowel syndrome in young men. Digestion. 2008;78:88–92. doi: 10.1159/000166600.
    1. Miller V, Whitaker K, Morris JA, Whorwell PJ. Gender and irritable bowel syndrome: the male connection. J Clin Gastroenterol. 2004;38:558–560. doi: 10.1097/00004836-200408000-00004.
    1. Aloisi AM, Bachiocco V, Costantino A, et al. Cross-sex hormone administration changes pain in transsexual women and men. Pain. 2007;132:S60–S67. doi: 10.1016/j.pain.2007.02.006.
    1. Chang L, Mayer EA, Labus JS, et al. Effect of sex on perception of rectosigmoid stimuli in irritable bowel syndrome. Am J Physiol Regul Integr Comp Physiol. 2006;291:R277–R284. doi: 10.1152/ajpregu.00729.2005.
    1. Ragnarsson G, Hallböök O, Bodemar G. Abdominal symptoms are not related to anorectal function in the irritable bowel syndrome. Scand J Gastroenterol. 1999;34:250–258. doi: 10.1080/00365529950173645.
    1. Naliboff BD, Berman S, Chang L, et al. Sex-related differences in IBS patients: central processing of visceral stimuli. Gastroenterology. 2003;124:1738–1747. doi: 10.1016/S0016-5085(03)00400-1.
    1. Chang L, Adeyemo M, Karagiannides I, et al. Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol. 2012;107:262–272. doi: 10.1038/ajg.2011.423.
    1. Martin-Viñas JJ, Quigley EM. Immune response in irritable bowel syndrome: a systematic review of systemic and mucosal inflammatory mediators. J Dig Dis. 2016;17:572–581. doi: 10.1111/1751-2980.12379.
    1. Cremon C, Gargano L, Morselli-Labate AM, et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol. 2009;104:392–400. doi: 10.1038/ajg.2008.94.
    1. Bashashati M, Rezaei N, Shafieyoun A, et al. Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterol Motil. 2014;26:1036–1048. doi: 10.1111/nmo.12358.
    1. Pigrau M, Rodiño-Janeiro BK, Casado-Bedmar M, et al. The joint power of sex and stress to modulate brain-gut microbiota axis and intestinal barrierhomeostasis: implications for irritable bowel syndrome. Neurogastroenterol Motil. 2016;28:463–486. doi: 10.1111/nmo.12717.
    1. Lee JY, Kim N, Kim YS, et al. Repeated water avoidance stress alters mucosal mast cell counts, interleukin-1β levels with sex difference in distal colon of wistar rats. J Neurogastroenterol Motil. 2016;22:694–704. doi: 10.5056/jnm16007.
    1. Mulak A, Taché Y, Larauche M. Sex hormones in the modulation of irritable bowel syndrome. World J Gastroenterol. 2014;20:2433–2448. doi: 10.3748/wjg.v20.i10.2433.
    1. Zheng G, Wu SP, Hu Y, Smith DE, Wiley JW, Hong S. Corticosterone mediates stress-related increased intestinal permeability in a regionspecific manner. Neurogastroenterol Motil. 2013;25:e127–e139. doi: 10.1111/nmo.12066.
    1. Honda J, Iijima K, Asanuma K, et al. Estrogen enhances esophageal barrier function by potentiating occludin expression. Dig Dis Sci. 2016;61:1028–1038. doi: 10.1007/s10620-015-3980-6.
    1. Cotter AA, Cashman KD. Effect of 17beta-oestradiol on transepithelial calcium transport in human intestinal-like Caco-2 cells and its interactions with 1,25-dihydroxycholecalciferol and 9-cis retinoic acid. Eur J Nutr. 2006;45:234–241. doi: 10.1007/s00394-006-0590-2.
    1. Braniste V, Leveque M, Buisson-Brenac C, Bueno L, Fioramonti J, Houdeau E. Oestradiol decreases colonic permeability through oestrogen receptor beta-mediated up-regulation of occludin and junctional adhesion molecule-A in epithelial cells. J Physiol. 2009;587(Pt 13):3317–3328. doi: 10.1113/jphysiol.2009.169300.
    1. Braniste V, Jouault A, Gaultier E, et al. Impact of oral bisphenol A at reference doses on intestinal barrier function and sex differences after perinatal exposure in rats. Proc Natl Acad Sci USA. 2010;107:448–453. doi: 10.1073/pnas.0907697107.
    1. Moussa L, Bézirard V, Salvador-Cartier C, Bacquié V, Houdeau E, Théodorou V. A new soy germ fermented ingredient displays estrogenic and protease inhibitor activities able to prevent irritable bowel syndrome-like symptoms in stressed female rats. Clin Nutr. 2013;32:51–58. doi: 10.1016/j.clnu.2012.05.021.
    1. Distrutti E, Monaldi L, Ricci P, Fiorucci S. Gut microbiota role in irritable bowel syndrome: new therapeutic strategies. World J Gastroenterol. 2016;22:2219–2241. doi: 10.3748/wjg.v22.i7.2219.
    1. Ait-Belgnaoui A, Payard I, Rolland C, et al. Bifidobacterium longum and Lactobacillus helveticus synergistically suppress stress-related visceral hypersensitivity through hypothalamic-pituitary-adrenal axis modulation. J Neurogastroenterol Motil. 2018;24:138–146. doi: 10.5056/jnm16167.
    1. Menon R, Watson SE, Thomas LN, et al. Diet complexity and estrogen receptor β status affect the composition of the murine intestinal microbiota. Appl Environ Microbiol. 2013;79:5763–5773. doi: 10.1128/AEM.01182-13.
    1. Markle JG, Frank DN, Mortin-Toth S, et al. Sex differences in the gut microbiome drive hormone dependent regulation of autoimmunity. Science. 2013;339:1084–1088. doi: 10.1126/science.1233521.
    1. Mattar AF, Teitelbaum DH, Drongowski RA, Yongyi F, Harmon CM, Coran AG. Probiotics up-regulate MUC-2 mucin gene expression in a Caco-2 cell-culture model. Pediatr Surg Int. 2002;18:586–590. doi: 10.1007/s00383-002-0855-7.
    1. Kim Y, Kim SH, Whang KY, Kim YJ, Oh S. Inhibition of Escherichia coli O157: H7 attachment by interactions between lactic acid bacteria and intestinal epithelial cells. J Microbiol Biotechnol. 2008;18:1278–1285.
    1. Da Silva S, Robbe-Masselot C, Ait-Belgnaoui A, et al. Stress disrupts intestinal mucus barrier in rats via mucin O-glycosylation shift: prevention by a probiotic treatment. Am J Physiol Gastrointest Liver Physiol. 2014;307:G420–G429. doi: 10.1152/ajpgi.00290.2013.
    1. Shastri P, McCarville J, Kalmokoff M, Brooks SP, Green-Johnson JM. Sex differences in gut fermentation and immune parameters in rats fed an oligofructose-supplemented diet. Biol Sex Differ. 2015;6:13. doi: 10.1186/s13293-015-0031-0.
    1. Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012;489:242–249. doi: 10.1038/nature11552.
    1. Kim SY, Choung RS, Lee SK, et al. Self reported sleep impairment in functional dyspepsia and irritable bowel syndrome. J Neurogastroenterol Motil. 2018;24:280–288. doi: 10.5056/jnm17098.
    1. Simrén M, Abrahamsson H, Svedlund J, Björnsson ES. Quality of life in patients with irritable bowel syndrome seen in referral centers versus primary care: the impact of gender and predominant bowel pattern. Scand J Gastroenterol. 2001;36:545–552. doi: 10.1080/003655201750153476.
    1. Choi YJ, Park YS, Kim N, et al. Gender differences in ghrelin, nociception genes, psychological factors and quality of life in functional dyspepsia. World J Gastroenterol. 2017;23:8053–8061. doi: 10.3748/wjg.v23.i45.8053.
    1. Park JM, Choi MG, Kim YS, et al. Quality of life of patients with irritable bowel syndrome in Korea. Qual Life Res. 2009;18:435–446. doi: 10.1007/s11136-009-9461-7.
    1. Corney RH, Stanton R. Physical symptom severity, psychological and social dysfunction in a series of outpatients with irritable bowel syndrome. J Psychosom Res. 1990;34:483–491. doi: 10.1016/0022-3999(90)90022-V.
    1. Faresjö A, Grodzinsky E, Johansson S, Wallander MA, Timpka T, Akerlind I. A population-based case-control study of work and psychosocial problems in patients with irritable bowel syndrome-women are more seriously affected than men. Am J Gastroenterol. 2007;102:371–379. doi: 10.1111/j.1572-0241.2006.01012.x.
    1. Halder SL, Locke GR, 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ., 3rd Impact of functional gastrointestinal disorders on health-related quality of life: a population-based case-control study. Aliment Pharmacol Ther. 2004;19:233–242. doi: 10.1111/j.0269-2813.2004.01807.x.
    1. Michalsen VL, Vandvik PO, Farup PG. Predictors of health-related quality of life in patients with irritable bowel syndrome. A cross-sectional study in Norway. Health Qual Life Outcomes. 2015;13:113. doi: 10.1186/s12955-015-0311-8.
    1. Hulme K, Chilcot J, Smith MA. Doctor-patient relationship and quality of life in irritable bowel syndrome: an exploratory study of the potential mediating role of illness perceptions and acceptance. Psychol Health Med. 2018;23:674–684. doi: 10.1080/13548506.2017.1417613.
    1. Frissora CL, Koch KL. The role of gender and biological sex in irritable bowel syndrome. Curr Gastroenterol Rep. 2005;7:257–263. doi: 10.1007/s11894-005-0017-x.
    1. Cheney AM. “Most girls want to be skinny”: body (dis)satisfaction among ethnically diverse women. Qual Health Res. 2011;21:1347–1359. doi: 10.1177/1049732310392592.
    1. Payne S. Sex, gender, and irritable bowel syndrome: making the connections. Gend Med. 2004;1:18–28. doi: 10.1016/S1550-8579(04)80007-X.
    1. Ali A, Toner BB, Stuckless N, et al. Emotional abuse, self-blame and self-silencing in women with irritable bowel syndrome. Psychosom Med. 2000;62:76–82. doi: 10.1097/00006842-200001000-00011.
    1. Björkman I, Dellenborg L, Ringström G, Simrén M, Jakobsson Ung E. The gendered impact of irritable bowel syndrome: a qualitative study of patients’ experiences. J Adv Nurs. 2014;70:1334–1343. doi: 10.1111/jan.12294.
    1. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22–32. doi: 10.1056/NEJMoa1004409.
    1. El-Serag HB. Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life. Rev Gastroenterol Disord. 2003;3(suppl 2):S3–S11.
    1. Gibson PR, Varney J, Malakar S, Muir JG. Food components and irritable bowel syndrome. Gastroenterology. 2015;148:1158–1174. e4. doi: 10.1053/j.gastro.2015.02.005.
    1. O’Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541–551. doi: 10.1053/j.gastro.2004.11.050.
    1. Ouyang A, Wrzos HF. Contribution of gender to pathophysiology and clinical presentation of IBS: should management be different in women? Am J Gastroenterol. 2006;101(12 suppl):S602–S609. doi: 10.1111/j.1572-0241.2006.00975.x.
    1. Lunsford TN, Harris LA. Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome. Int J Womens Health. 2010;2:361–374.
    1. Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther. 1999;13:1149–1159. doi: 10.1046/j.1365-2036.1999.00610.x.
    1. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet. 2000;355:1035–1040. doi: 10.1016/S0140-6736(00)02033-X.
    1. Katsumata R, Shiotani A, Murao T, et al. Gender differences in serotonin signaling in patients with diarrhea-predominant irritable bowel syndrome. Intern Med. 2017;56:993–999. doi: 10.2169/internalmedicine.56.7674.
    1. Scott LJ, Perry CM. Tegaserod. Drugs. 1999;58:491–496. doi: 10.2165/00003495-199958030-00013. discussion 497–498.
    1. Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol. 2005;100:115–123. doi: 10.1111/j.1572-0241.2005.40365.x.
    1. Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009;104:1831–1843. doi: 10.1038/ajg.2009.223.
    1. Zheng Y, Yu T, Tang Y, et al. Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2017;12:e0172846. doi: 10.1371/journal.pone.0172846.
    1. Ringel Y, Carroll IM. Alterations in the intestinal microbiota and functional bowel symptoms. Gastrointest Endosc Clin N Am. 2009;19:141–150. vii. doi: 10.1016/j.giec.2008.12.004.
    1. Camilleri M, Atanasova E, Carlson PJ, et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2002;123:425–432. doi: 10.1053/gast.2002.34780.
    1. Garsed K, Chernova J, Hastings M, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut. 2014;63:1617–1625. doi: 10.1136/gutjnl-2013-305989.
    1. Lee KJ, Kim NY, Kwon JK, et al. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. Neurogastroenterol Motil. 2011;23:1098–1104. doi: 10.1111/j.1365-2982.2011.01771.x.
    1. Fukudo S, Ida M, Akiho H, Nakashima Y, Matsueda K. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol. 2014;12:953–959.e4. doi: 10.1016/j.cgh.2013.11.024.
    1. Fukudo S, Kinoshita Y, Okumura T, et al. Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women. Gastroenterology. 2016;150:358–366.e8. doi: 10.1053/j.gastro.2015.10.047.
    1. Lembo A, Pimentel M, Rao SS, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2016;151:1113–1121. doi: 10.1053/j.gastro.2016.08.003.
    1. Ford AC, Quigley EM, Lacy BE, et al. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2014;109:1350–1365. doi: 10.1038/ajg.2014.148.
    1. Lee HH, Choi YY, Choi MG. The Efficacy of hypnotherapy in the treatment of irritable bowel syndrome: a systematic reviewand meta-analysis. J Neurogastroenterol Motil. 2014;20:152–162. doi: 10.5056/jnm.2014.20.2.152.
    1. Ustün TB. Cross-national epidemiology of depression and gender. J Gend Specif Med. 2000;3:54–58.
    1. Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther. 2007;25:1351–1361. doi: 10.1111/j.1365-2036.2007.03320.x.
    1. Buscail C, Sabate JM, Bouchoucha M, et al. Association between self-reported vegetarian diet and the irritable bowel syndrome in the French-NutriNet cohort. PLoS One. 2017;12:e0183039. doi: 10.1371/journal.pone.0183039.
    1. Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med. 2011;365:527–536. doi: 10.1056/NEJMoa1010863.
    1. Barshop K, Staller K. Eluxadoline in irritable bowel syndrome with diarrhea: rationale, evidence and place in therapy. Ther Adv Chronic Dis. 2017;8:153–160. doi: 10.1177/2040622317714389.
    1. Schumann D, Klose P, Lauche R, Dobos G, Langhorst J, Cramer H. Low fermentable, oligo-, di-, mono-saccharides and polyol diet in the treatment of irritable bowel syndrome: a systematic review and meta-analysis. Nutrition. 2018;45:24–31. doi: 10.1016/j.nut.2017.07.004.
    1. Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol. 2008;103:170–177. doi: 10.1111/j.1572-0241.2007.01524.x.
    1. Fukudo S, Kinoshita Y, Okumura T, et al. Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study. J Gastroenterol. 2016;51:874–882. doi: 10.1007/s00535-016-1165-5.
    1. Qi Q, Zhang Y, Chen F, Zuo X, Li Y. Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials. BMC Gastroenterol. 2018;18:5. doi: 10.1186/s12876-017-0734-2.
    1. Heils A, Teufel A, Petri S, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem. 1996;66:2621–2624. doi: 10.1046/j.1471-4159.1996.66062621.x.
    1. Choi YJ, Hwang SW, Kim N, Park JH, Oh JC, Lee DH. Association between SLC6A4 serotonin transporter gene linked polymorphic region and ADRA2A 1291C>G and irritable bowel syndrome in Korea. J Neurogastroenterol Motil. 2014;20:388–399. doi: 10.5056/jnm14020.
    1. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012;107:1702–1712. doi: 10.1038/ajg.2012.254.
    1. Lembo AJ, Lacy BE, Zuckerman MJ, et al. Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J Med. 2016;374:242–253. doi: 10.1056/NEJMoa1505180.
    1. Ford AC, Talley NJ, Spiegel BM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2008;337:a2313. doi: 10.1136/bmj.a2313.
    1. Anderson GD. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Womens Health (Larchmt) 2005;14:19–29. doi: 10.1089/jwh.2005.14.19.
    1. Tran C, Knowles SR, Liu BA, Shear NH. Gender differences in adverse drug reactions. J Clin Pharmacol. 1998;38:1003–1009. doi: 10.1177/009127009803801103.
    1. Kaiser J. Gender in the pharmacy: does it matter? Science. 2005;308:1572. doi: 10.1126/science.308.5728.1572.
    1. Rademaker M. Do women have more adverse drug reactions? Am J Clin Dermatol. 2001;2:349–351. doi: 10.2165/00128071-200102060-00001.
    1. Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet. 2002;41:329–342. doi: 10.2165/00003088-200241050-00002.
    1. Yamada E, Tsunoda S, Abe T, et al. Factors associated with poor therapeutic response in outpatients with irritable bowel syndrome: a multi-center study in Japan. J Gastroenterol. 2017;52:301–307. doi: 10.1007/s00535-016-1215-z.
    1. Creed F. The relationship between psychosocial parameters and outcome in irritable bowel syndrome. Am J Med. 1999;107(5A):74S–80S. doi: 10.1016/S0002-9343(99)00083-2.
    1. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010;59:325–332. doi: 10.1136/gut.2008.167270.
    1. Dai C, Zheng CQ, Jiang M, Ma XY, Jiang LJ. Probiotics and irritable bowel syndrome. World J Gastroenterol. 2013;19:5973–5980. doi: 10.3748/wjg.v19.i36.5973.
    1. Lee BJ, Bak YT. Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil. 2011;17:252–266. doi: 10.5056/jnm.2011.17.3.252.
    1. Zahedi MJ, Behrouz V, Azimi M. Low fermentable oligo-di-monosaccharides and polyols diet versus general dietary advice in patients with diarrhea-predominant irritable bowel syndrome: a randomized controlled trial. J Gastroenterol Hepatol. 2018;33:1192–1199. doi: 10.1111/jgh.14051.
    1. Lacy BE, Weiser K, Noddin L, et al. Irritable bowel syndrome: patients’ attitudes, concerns and level of knowledge. Aliment Pharmacol Ther. 2007;25:1329–1341. doi: 10.1111/j.1365-2036.2007.03328.x.
    1. Cuomo R, Andreozzi P, Zito FP, Passananti V, De Carlo G, Sarnelli G. Irritable bowel syndrome and food interaction. World J Gastroenterol. 2014;20:8837–8845.
    1. Böhn L, Störsrud S, Liljebo T, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology. 2015;149:1399–1407.e2. doi: 10.1053/j.gastro.2015.07.054.
    1. Jung KW, Seo M, Cho YH, et al. Prevalence of fructose malabsorption in patients with irritable syndrome after excluding small intestinal bacterial overgrowth. J Neurogastroenterol Motil. 2018;24:307–316. doi: 10.5056/jnm17044.
    1. Kim Y, Choi CH. Role of fructose malabsorption in patients with irritable bowel syndrome. J Neurogastroenterol Motil. 2018;24:161–163. doi: 10.5056/jnm18057.
    1. Böhn L, Störsrud S, Törnblom H, Bengtsson U, Simrén M. Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life. Am J Gastroenterol. 2013;108:634–641. doi: 10.1038/ajg.2013.105.
    1. Varjú P, Farkas N, Hegyi P, et al. Low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet improves symptoms in adults suffering from irritable bowel syndrome (IBS) compared to standard IBS diet: a meta-analysis of clinical studies. PLoS One. 2017;12:e0182942. doi: 10.1371/journal.pone.0182942.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅